No Relationship of Lipid-Lowering Agents to @entity1410 Growth: Pooled Analysis of the Intensive Blood Pressure Reduction in Acute XXXX Trials Studies.

@entity1 @entity1410 @entity1779
BACKGROUND AND PURPOSE: Controversy persists over statins and risk of @entity1779 . We determined associations of premorbid lipid-lowering therapy and outcomes among @entity1 of the Intensive Blood Pressure Reduction in Acute @entity1779 Trials (INTERACT). METHODS: The pooled data of INTERACT 1 and 2 (international, multicenter, prospective, open, blinded end point, randomized controlled trials of @entity1 with @entity1779 [<6 hours] and elevated systolic blood pressure) were analyzed with regard to associations of baseline lipid-lowering treatment and clinical outcomes of 3184 @entity1 in a multivariate model. Associations of lipid-lowering therapy and @entity1410 growth (baseline to 24 hours) in computed tomographic substudies @entity1 (n=1310) were estimated in ANCOVA. RESULTS: Among 204 @entity1 (6.5%) with baseline lipid-lowering treatment, 90-day clinical outcomes were not significantly different after adjustment for confounding variables including region and age. In the computed tomographic substudy, 24-hour @entity1410 growth was greater in 124 @entity1 (9%) with, compared with those without, prior lipid-lowering therapy. However, this association was not significant between groups (9.2 versus 6.8 mL; P<0.13), after adjustment for prior antithrombotic therapy. CONCLUSIONS: No independent associations were found between lipid-lowering medication and adverse outcomes in @entity1 with @entity1779 . CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00226096 and NCT00716079.
